ERBB2 and neoplasm: Mechanistically, loss of the tumour suppressor SPRY2 leads to activation of the HER2‐IL6 cytokine signalling axis, which enhances tumoral expression of androgen biosynthetic enzyme HSD3B1 and lipoprotein receptor SRB1.